| Study ID | Study follow‐up (months) | CoronaVac/boost Ad5‐vectored (n) | CoronaVac/boost (n) | Critical outcomes | |||||||||
| Confirmed SARS‐CoV‐2 infection after complete vaccination | Confirmed symptomatic COVID‐19 after complete vaccination | Severe or critical COVID‐19 | All‐cause mortality | Systemic reactogenicity events | Any AE | SAE | |||||||
| Li 2021a (NCT04892459) | 1 | 100 | 100 | * | * | * | * | ✓ | ✓ | ✓ | |||
| Important outcomes | |||||||||||||
| GMT of specific antibody against SARS‐COV‐2 | GMT of neutralizing antibody against SARSCOV‐2 | Local reactogenicity events | |||||||||||
| ✓ | ✓ | ✓ | |||||||||||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.